Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms
Summary
HERCULES, Calif.--( BUSINESS WIRE )--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments.Bio-Rad is a global leader of quality control products, offering an extensive range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing.The company’s QC data management solutions connect large peer groups of test systems and assay methods to the company’s Unity Interlaboratory Program, enabling labs to compare their results in real time with over 25,000 other labs worldwide.With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare.Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.